-
Global Biopharma Layoffs March 2026
Layoffs
Global Biopharma companies including Merck, Baye, and Novartis announce workforce reductions in March 2026 as part of cost-saving and strategic realignments, impacting research, technology, and leadership roles across their operations.
-
Global Biopharma Layoffs January 2026
Layoffs
This article tracks recent biotech and pharma layoffs, including major workforce cuts at Voyager Therapeutics, Intercept Pharmaceuticals, Mythic Therapeutics, Pfizer, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
-
Global Biopharma Layoffs October 2025
Layoffs
This article tracks recent biotech and pharma layoffs, including major workforce cuts at Novo Nordisk, Takeda, GSK, Pharming, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
-
Takeda's 2024 Financial report
Market Trend
Takeda projects $11B in peak sales from three key drug candidates—TAK-279, TAK-861, and TAK-121—while restructuring its pipeline to drive future growth and profitability.
-
Takeda Shuts Down EGFR, B7-H3 Programs
Takeda
Takeda announces major R&D cuts, discontinuing EGFR and B7-H3 oncology projects from its $525M Maverick deal, and streamlining other pipelines to focus on high-potential therapies.
-
Takeda's 2024 Q4 Financial report
Market Trend
Takeda's 2024 fiscal report shows 7.4% revenue growth to ￥4.58T, driven by strong core business and R&D breakthroughs. Key segments include GI, rare diseases, oncology. Outlook for 2025 remains stable despite VYVANSE competition.
-
-
Takeda 2024 Q3 Financial Report
Financial statements
Takeda’s 2024 financial report shows a $290M revenue for Fuquatinib and strong growth across its key segments. The company also announces CEO succession with Julie Kim to succeed Christophe Weber in 2026.
-
Top 10 Immunology Drugs to Watch in 2024
AbbVie
Explore the top 10 best-selling immunology drugs of 2023, including Humira, Dupixent, Stelara, and more. Discover how these innovative therapies are shaping the market, driving clinical breakthroughs, and overcoming competitive challenges.
-
Takeda Q2 2024 Financial Results
Financial statements
Takeda's Q2 2024 results show strong performance with total revenue of 2.384 trillion yen and upgraded full-year forecasts. Key highlights include Fruquintinib's overseas sales reaching 23.1 billion yen, driven by significant growth in the U.S. market.
主站蜘蛛池模板：
日韩 欧美 综合
|
伊人免费在线
|
久久一区|
www黄在线观看
|
91精品国产综合久久久密臀九色
|
日韩在线视频网站
|
色九九
|
亚洲成人激情在线
|
在线小视频你懂的
|
久在线观看
|
久久亚洲精品小早川怜子66
|
成人深夜福利
|
天堂av免费看
|
蜜臀tv|
国产日韩精品一区二区三区
|
国产黄色免费
|
ww国产|
天天有av|
亚洲一区在线看
|
99免费精品
|
一区二区三区四区亚洲
|
中文字幕综合在线
|
国产精品不卡视频
|
亚洲女优在线观看
|
麻豆做爰免费观看
|
在线观看中文字幕一区
|
天天插综合网
|
夜夜天天操
|
四虎影院久久
|
日韩欧美精品在线
|
日韩午夜精品
|
午夜黄色大片
|
国产9区
|
日本欧美一区二区三区
|
国产传媒自拍
|
精品一区在线
|
伊人免费视频
|
女人毛片
|
国产三级福利
|
中文在线第一页
|
日本高清黄色
|
